Uveal melanoma is a rare cancer that develops in the eye and leads to metastasis in 50% of patients, with an incidence of 2–8 cases per million inhabitants in Europe
Scientists from the University of Granada and GENYO have published their results in the journal Cancers
Scientists from the University of Granada and GENYO (Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research), in a study led by Juan Carlos Rodríguez-Manzaneque, have demonstrated the significant role of a protein called ADAMTS1 in uveal melanoma, one of the rarest and most aggressive cancers that exist, which develops in the eye.
Tumours are composed not only of a mass of cells that grow uncontrollably but also of the environment they create during their growth—together creating what is known as the ‘tumour microenvironment’. Within this environment, there are proteins that remodel it, known as extracellular proteases, which are capable of inhibiting or contributing to tumour growth and metastasis. They do this by modifying non-cellular elements of the tumour microenvironment that form the so-called extracellular matrix.
In this study, published in the journal Cancers, the researchers studied the role that one of these proteases, ADAMTS1, plays in the development of a rare and highly-aggressive subtype of melanoma: uveal melanoma. Uveal melanoma develops in the eye, although 50% of patients develop metastasis, and it has an incidence of 2–8 cases per million inhabitants in Europe
“In this research, we demonstrated that the ADAMTS1 protease is necessary for cancer cells to mimic endothelial cells (responsible for forming blood vessels), which is related to more aggressive tumours and a worse clinical prognosis,” explains Carlos Peris Torres, the main author of the work.
To do this, the researchers inhibited the ADAMTS1 protease using CRISPR/Cas9 gene-editing technology. This is a molecular tool used to ‘edit’ or ‘correct’ the genome of any cell (its developers, Emmanuelle Charpentier and Jennifer A. Doudna, having won this year’s Nobel Prize for Chemistry). The researchers then verified the outcomes of their intervention on the protease in in vitro models with cell lines, and in vivo with different mouse models.
Bioinformatic tools
In addition, using advanced bioinformatic tools and publicly-available data on uveal melanomas (from the Cancer Genome Atlas Project, developed by the US National Cancer Institute, which holds data on more than 20,000 samples of 33 different types of cancer), the UGR and GENYO scientists found new genes whose expression affects the clinical prognosis of this tumour type.
“These include several members of the ADAMTS family and endothelial genes such as CDH5 and KDR. A more detailed analysis also revealed a high expression of ADAMTS1 in the initial stages of uveal melanoma, which confirmed its contribution to the initiation of tumour development and corroborated the results obtained experimentally”, adds Peris Torres.
In light of these results, the researchers have concluded that ADAMTS1 is necessary for the development of uveal melanoma. This study is also the first to support the development of therapeutic targets aimed at the extracellular matrix to combat uveal melanoma.
Bibliography:
Peris-Torres, C., Plaza-Calonge, M.C., López-Domínguez, R., Domínguez-García, S., Barrientos-Durán, A., Carmona-Sáez, P., and Rodríguez-Manzaneque, J.C. (2020) ‘Extracellular Protease ADAMTS1 is Required at Early Stages of Human Uveal Melanoma Development by Inducing Stemness and Endothelial-Like Features on Tumor Cells’, Cancers 12, 801. https://doi.org/10.3390/cancers12040801
Media enquiries:
Carlos Peris Torres
Pfizer-University of Granada-Andalusian Government Centre for Genomics and Oncological Research (GENYO), Area of Genomic Oncology
Email: carpeto@correo.ugr.es
